Esperion Therapeutics ESPR Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's total liabilities & equity?
- Esperion Therapeutics (ESPR) reported total liabilities & equity of $462.53M in Q1 2026.
- How has Esperion Therapeutics's total liabilities & equity changed year-over-year?
- Esperion Therapeutics's total liabilities & equity increased by 42.7% year-over-year, from $324.03M to $462.53M.
- What is the long-term trend for Esperion Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Esperion Therapeutics's total liabilities & equity has grown at a 5.7% compound annual growth rate (CAGR), from $353.26M to $465.89M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.